Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Harvard Business School
McKesson
Moodys
Mallinckrodt

Last Updated: June 28, 2022

Loxo Oncology Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for LOXO ONCOLOGY INC, and what generic alternatives to LOXO ONCOLOGY INC drugs are available?

LOXO ONCOLOGY INC has one approved drug.

There are five US patents protecting LOXO ONCOLOGY INC drugs.

There are sixty-six patent family members on LOXO ONCOLOGY INC drugs in thirty-six countries.

Summary for Loxo Oncology Inc
International Patents:66
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Loxo Oncology Inc

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-002 May 8, 2020 RX Yes Yes 10,137,124 See Plans and Pricing See Plans and Pricing
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-002 May 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No See Plans and Pricing See Plans and Pricing
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No 10,112,942 See Plans and Pricing Y Y See Plans and Pricing
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No 10,172,851 See Plans and Pricing See Plans and Pricing
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No 10,584,124 See Plans and Pricing Y See Plans and Pricing
Loxo Oncology Inc RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No 10,786,489 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Sign up for a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Dow
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2022 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
 NCE-1 Patent Challenge Dates 2022 - 2023
 ClinicalTrialExchange - Connecting volunteers and trials
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group